Cargando…
Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
The present study aimed to investigate the usefulness of the Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative stratification of patients with ovarian tumors using a novel combination of laboratory tests. The study group (n=619) consisted of 354 premenopausal and 265 postmenopausal pat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103905/ https://www.ncbi.nlm.nih.gov/pubmed/27899969 http://dx.doi.org/10.3892/ol.2016.5058 |
_version_ | 1782466660930682880 |
---|---|
author | Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Luterek-Puszyńska, Katarzyna Menkiszak, Janusz |
author_facet | Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Luterek-Puszyńska, Katarzyna Menkiszak, Janusz |
author_sort | Chudecka-Głaz, Anita |
collection | PubMed |
description | The present study aimed to investigate the usefulness of the Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative stratification of patients with ovarian tumors using a novel combination of laboratory tests. The study group (n=619) consisted of 354 premenopausal and 265 postmenopausal patients. The levels of carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) were determined, and ROMA calculations were performed for each pre- and postmenopausal patient. HE4 levels were determined using an electrochemiluminescence immunoassay, while CA125 levels were determined by a chemiluminescence microparticle immunoassay. A contingency table was applied to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Receiver operating characteristic curves were also constructed, and areas under the curves (AUCs) were compared between the marker determinations and ROMA algorithms. In terms of distinguishing between ovarian cancer and benign disease, the sensitivity of ROMA was 88.3%, specificity was 88.2%, PPV was 75.3% and NPV was 94.9% among all patients. The respective parameters were 71.1, 90.1, 48.2 and 91.1% in premenopausal patients and 93.6, 82.9, 86.6 and 91.6% in postmenopausal patients. The AUC value for the ROMA algorithm was 0.926 for the ovarian cancer vs. benign groups in all patients, 0.813 in premenopausal patients and 0.939 in postmenopausal patients. The respective AUC values were 0.911, 0.879 and 0.934 for CA125; and 0.879, 0.783 and 0.889 for HE4. In this combination, the ROMA algorithm is characterized by an extremely high sensitivity of prediction of ovarian cancer in women with pelvic masses, and may constitute a precise tool with which to support the qualification of patients to appropriate surgical procedures. The ROMA may be useful in diagnosing ovarian endometrial changes in young patients. |
format | Online Article Text |
id | pubmed-5103905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-51039052016-11-29 Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Luterek-Puszyńska, Katarzyna Menkiszak, Janusz Oncol Lett Articles The present study aimed to investigate the usefulness of the Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative stratification of patients with ovarian tumors using a novel combination of laboratory tests. The study group (n=619) consisted of 354 premenopausal and 265 postmenopausal patients. The levels of carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) were determined, and ROMA calculations were performed for each pre- and postmenopausal patient. HE4 levels were determined using an electrochemiluminescence immunoassay, while CA125 levels were determined by a chemiluminescence microparticle immunoassay. A contingency table was applied to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Receiver operating characteristic curves were also constructed, and areas under the curves (AUCs) were compared between the marker determinations and ROMA algorithms. In terms of distinguishing between ovarian cancer and benign disease, the sensitivity of ROMA was 88.3%, specificity was 88.2%, PPV was 75.3% and NPV was 94.9% among all patients. The respective parameters were 71.1, 90.1, 48.2 and 91.1% in premenopausal patients and 93.6, 82.9, 86.6 and 91.6% in postmenopausal patients. The AUC value for the ROMA algorithm was 0.926 for the ovarian cancer vs. benign groups in all patients, 0.813 in premenopausal patients and 0.939 in postmenopausal patients. The respective AUC values were 0.911, 0.879 and 0.934 for CA125; and 0.879, 0.783 and 0.889 for HE4. In this combination, the ROMA algorithm is characterized by an extremely high sensitivity of prediction of ovarian cancer in women with pelvic masses, and may constitute a precise tool with which to support the qualification of patients to appropriate surgical procedures. The ROMA may be useful in diagnosing ovarian endometrial changes in young patients. D.A. Spandidos 2016-11 2016-08-29 /pmc/articles/PMC5103905/ /pubmed/27899969 http://dx.doi.org/10.3892/ol.2016.5058 Text en Copyright: © Chudecka-Głaz et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Luterek-Puszyńska, Katarzyna Menkiszak, Janusz Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title_full | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title_fullStr | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title_full_unstemmed | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title_short | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125 |
title_sort | diagnostic usefulness of the risk of ovarian malignancy algorithm using the electrochemiluminescence immunoassay for he4 and the chemiluminescence microparticle immunoassay for ca125 |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103905/ https://www.ncbi.nlm.nih.gov/pubmed/27899969 http://dx.doi.org/10.3892/ol.2016.5058 |
work_keys_str_mv | AT chudeckagłazanita diagnosticusefulnessoftheriskofovarianmalignancyalgorithmusingtheelectrochemiluminescenceimmunoassayforhe4andthechemiluminescencemicroparticleimmunoassayforca125 AT cymbalukpłoskaaneta diagnosticusefulnessoftheriskofovarianmalignancyalgorithmusingtheelectrochemiluminescenceimmunoassayforhe4andthechemiluminescencemicroparticleimmunoassayforca125 AT luterekpuszynskakatarzyna diagnosticusefulnessoftheriskofovarianmalignancyalgorithmusingtheelectrochemiluminescenceimmunoassayforhe4andthechemiluminescencemicroparticleimmunoassayforca125 AT menkiszakjanusz diagnosticusefulnessoftheriskofovarianmalignancyalgorithmusingtheelectrochemiluminescenceimmunoassayforhe4andthechemiluminescencemicroparticleimmunoassayforca125 |